

**This Page Is Inserted by IFW Operations
and is not a part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/127, 9/72, 31/56		A1	(11) International Publication Number: WO 96/19199 (43) International Publication Date: 27 June 1996 (27.06.96)
(21) International Application Number: PCT/SE95/01560 (22) International Filing Date: 20 December 1995 (20.12.95) (30) Priority Data: 9404466-6 22 December 1994 (22.12.94) SE 9502369-3 30 June 1995 (30.06.95) SE (71) Applicant (for all designated States except US): ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE). (72) Inventors; and (75) Inventors/Applicants (for US only): BYSTRÖM, Katarina [SE/SE]; Vämen, Kullavägen, S-240 13 Genarp (SE). NILSSON, Per-Gunnar [SE/SE]; Betrandsgatan 2 A, S-212 14 Malmö (SE). (74) Agent: ASTRA AKTIEBOLAG; Patent Dept., S-151 85 Södertälje (SE).		(81) Designated States: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG). Published With international search report.	
(54) Title: PROLIPOSOME POWDERS FOR INHALATION			
(57) Abstract A proliposome powder, said powder comprising in a single phase discrete particles of a biologically active component together with a lipid or mixture of lipids having a phase transition temperature of below 37 °C.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

PROLIPOSOME POWDERS FOR INHALATION

Field of the invention

- 5 The present invention relates to proliposome powders, particularly for inhalation, a process for producing the proliposome powders, compositions containing the proliposome powders and methods for their use.

Technical background

- 10 Liposomes are membrane-like vesicles consisting of series of concentric lipid bilayers alternating with hydrophilic compartments. They can be made from a variety of natural and synthetic lipids such as natural and synthetic phosphoglycerolipids, sphingolipids, and digalactosylglycerolipids. One of the main uses for liposomes has been as carriers for different kinds of pharmaceutically active components, in order to improve drug delivery
- 15 and to minimise side-effects of some treatments. The pharmaceutically active components can be incorporated into liposomes either by encapsulation in hydrophilic compartments of the liposome (when the active component is water-soluble), or by encapsulation into the lipid bilayers, when the active component is lipophilic.
- 20 One of the major problems associated with pharmaceutical liposomal formulations is the long-term stability. Aqueous liposome dispersions have a limited stability due to aggregation, loss of the encapsulated active component to the external phase, chemical degradation of the active component or the lipid material, etc.
- 25 These problems can to a large extent be overcome if a solid composition is used. Such a solid composition can comprise a liposome powder, i.e. a dried liposome dispersion or a proliposome powder.

The process of drying liposome dispersions has the associated risk of damage to the liposome membranes. In order to minimise this risk it is necessary to dry the liposomes in the presence of protective sugars, as described for example in WO 86/01103.

5 US patent number 4,906,476 discloses liposome formulations for the delivery of steroids by inhalation. The possibility of delivering dried liposomes as a powder aerosol using a suitable device is disclosed. Delivery by spraying from a self-contained atomiser using a propellant solvent with suspended dried liposomes in a powder, and by spraying dried particles into the lungs with a propellant, is also disclosed.

10

Liposomes as such are not present in proliposome powders, but are formed when the powder is hydrated above the phase transition temperature of the lipids. Compared with dried liposomes, proliposome powders therefore have the advantage that the risk of damage to the liposome membranes on dehydration is eliminated.

15

Proliposome powders have been described previously.

For example, US patent 4,311,712 discloses a freeze-dried potential liposome mixture obtained by dissolving a liposome-forming amphipathic lipid and a lipid-soluble or lipid-bound biologically active compound in an organic solvent which remains solid during the freeze-drying process, and freeze-drying the solution. The potential liposome mixture may be stored and made up into an aqueous liposome preparation when desired. The biologically active compound may be any compound having a property of biological interest.

25

WO 90/00389 discloses a freeze-dried potential liposome mixture having an amphipathic lipid and a cyclosporin or derivative thereof, for use in possible liposome delivery of cyclosporin into cells. The freeze-dried mixture is reconstituted in aqueous medium to yield liposomes which encapsulate substantially all of the cyclosporin present in the freeze-dried mixture.

30

WO 92/11842 discloses a preliposomal powder which forms a suspension of liposomes containing a polyene drug such as nystatin when reconstituted with water or saline solution.

All of the above patents and applications concerning proliposome compositions are
5 concerned with compositions which are to be hydrated prior to administration.

EP 309464 describes proliposome powder compositions which may be inhaled. The powder compositions comprise solid particles in which a biologically active component is in particulate dispersion in a lipid.

10

Object of the invention

We have found it advantageous to provide proliposome powders having only a single phase when delivery by inhalation is desired. Therefore it is an object of the present invention to provide such a proliposome powder.

15

Disclosure of the invention

The above object of the present invention is achieved in the provision according to the present invention of a proliposome powder, said powder comprising in a single phase discrete particles of a biologically active component together with a lipid or mixture of
20 lipids having a phase transition temperature (T_c) of below 37°C.

The powder is particularly suitable for administration by inhalation.

The single phase powder may alternately be described as comprising a homogeneous
25 molecular mixture of a biologically active component and a lipid or mixture of lipids having a phase transition temperature of below 37°C.

It will be understood from the terms "single phase" and "homogeneous molecular mixture" that there is no separate crystalline phase of either active component or lipid in the powder
30 of the present invention.

The single phase powder can be inhaled directly and in situ, for example in the upper or lower respiratory system, will form liposomes in which a biologically active component is totally incorporated.

5 In general, any amphipathic lipid or mixture of lipids known to be suitable for preparing liposomes by known methods could be used in the present invention. The lipid or lipid mixture must have a phase-transition temperature below body temperature (37°C) in order for the product proliposome powder to be capable of hydration under physiological conditions (i.e. in order to be able to form liposomes in the respiratory system). Phase-
10 transition temperatures for different lipid mixtures may be estimated easily, using well-established methods, for example DSC methods - see for example J. Suurkuusk et al., *Biochemistry*, vol. 15, no.7, p. 1393 (1976). In general any natural or synthetic lipid or mixture of lipids having a phase transition temperature below 37°C are useful in the present invention.

15 As examples of potentially useful lipids may be mentioned natural and synthetic lipids such as natural and synthetic phosphoglycerolipids, sphingolipids, and digalactosylglycerolipids. Amongst natural lipids may be mentioned sphingolipids (SL) such as sphingomyelin (SM), ceramide and cerebroside; galactosylglycerolipids such as digalactosyldiacylglycerol
20 (DGalDG); phosphoglycerolipids such as egg-yolk phosphatidylcholin (e-PC) and soya-bean phosphatidylcholin (s-PC); and lecithins such as egg-yolk lecithin (e-lecithin) and soya-bean lecithin (s-lecithin). Amongst synthetic lipids may be mentioned dimyristoyl phosphatidylcholin (DMPC), dipalmitoyl phosphatidylcholin (DPPC), distearoyl phosphatidylcholin (DSPC), dilauryl phosphatidylcholin (DLPC), 1-myristoyl-2-palmitoyl
25 phosphatidylcholin (MPPC), 1-palmitoyl -2-myristoyl phosphatidylcholin (PMPC), and dioleoyl phosphatidylcholin (DOPC). Amongst mixtures of lipids may be mentioned the following: SM/PC, SM/Cholesterol, ePC/Cholesterol, sPC/Cholesterol, PC/PS/Cholesterol, DMPC/DPPC, DMPC/DPPC/CH, DMPC/CH, DPPC/DOPC, DPPC/DOPC/CH, DLPC/DPPC, DLPC/DPPC/CH, DLPC/DMPC, DLPC/DMPC/CH, DOPC/DSPC,
30 DPSM/DMSM, e-lecithin/Cholesterol and s-lecithin/Cholesterol. In addition to any of the

above there may be included a charged lipid such as dimyristoyl phosphatidylglycerol (DMPG), diphosphatidyl phosphatidylglycerol (DPPG), dimyristoyl phosphatidic acid (DMPA), dipalmitoyl phosphatidic acid (DPPA) or stearylamine (SA).

5 Lipids of particular interest in the present invention are DPPC and / or DMPC. A mixture of DPPC and DMPC containing at least 10% (w/w) DMPC is preferred, for example 10-50% DMPC. Especially preferred is a mixture of DPPC and DMPC containing in addition at least one charged lipid such as DMPG, DPPG, DMPA or SA, for example in an amount of up to 5% (w/w). Other preferred mixtures include DPSM and DMSM optionally
10 containing at least one charged lipid, and mixtures of cholesterol with either *c*-lecithin or *s*-lecithin, optionally containing at least one charged lipid, and having a T_c of less than 37°C. Other mixtures can be selected easily by a person skilled in the art with reference for example to Gregor Cevc, *Phospholipids Handbook*, Marcel Dekker, New York (1993) pp 427-435.

15

The active component preferably has a molecular structure which can be incorporated into the lipid bilayers, to aid encapsulation in the liposomes during hydration. An example of such is a fatty acid ester having a long hydrocarbon chain sufficient to act as hydrophobic anchor.

20

Suitable active components can be identified readily by a person skilled in the art and may include for example antiinflammatory and bronchorelaxing drugs as well as antihistamines, cyclooxygenase inhibitors, leukotriene synthesis inhibitors, leukotriene antagonists, phospholipase-A2 (PLA2) inhibitors, platelet aggregating factor (PAF) antagonists and
25 prophylactics of asthma. Antiarrhythmic drugs, tranquilisers, cardiac glycosides, hormones, anti-hypertensive drugs, antidiabetic, antiparasitic and anticancer drugs, sedatives, analgesic drugs, antibiotics, antirheumatic drugs, immunotherapies, antifungal drugs, antihypotension drugs, vaccines, antiviral drugs, proteins, peptides and vitamins, may also be of interest.

30

Specifically, glucocorticosteroids such as budesonide, dexamethasone, bethamethasone, fluocinolone, flumethasone, triamcinolone acetonide, flunisolide, beclomethasone and 16, 17-acetals of pregnane derivatives and compounds derived therefrom; and β -2 agonists such as terbutaline, salmeterol, salbutamol, formoterol, fenoterol, clenbuterol, procaterol, bitolterol, and broxaterol may be useful in the present invention. The active component may also be a mixture of pharmaceutically active substances; for example a mixture of a glucocortico-steroid with a bronchodilator such as formoterol, salmeterol, terbutaline or salbutamol, may be useful. For the avoidance of doubt, where a reference to any active component is made herein, said reference is intended to include a reference to pharmaceutically acceptable esters, salts, and hydrates thereof.

Where the active component is a steroid it is preferably a steroid ester.

The active component is preferably a steroid, preferably a steroid which is esterified in 21-position with a fatty acid of at least 8, for example at least 10 or at least 12 carbon atoms. The fatty acid may have, for example, up to 24 carbon atoms, for example up to 20 carbon atoms or up to 18 carbon atoms. More preferably, the active component is a steroid-21-palmitate, myristate, laurate, caprate, caprylate or stearate. The most preferred active component according to the invention is the compound (22R)-16 α ,17 α -butylenedioxy-6 α ,9 α -difluoro-11 β -hydroxy-21-palmitoyloxy-4-ene-3,20-dione, rofleponide palmitate.

Where the active component is an ester it must be hydrolysed to the active principal.

Surprisingly, the single phase proliposome powder of the present invention facilitates the necessary hydrolysis in situ, whereas esters in the crystalline state will not be hydrolysed.

Where delivery by inhalation is desired, as much as possible of the proliposome powder of the present invention should consist of particles having a diameter of less than 10 microns, for example 0.01-10 microns or 0.1-6 microns, for example 0.1-5 microns, or agglomerates of said particles. Preferably at least 50% of the powder consists of particles within the

desired size range. For example at least 60%, preferably at least 70%, more preferably at least 80% and most preferably at least 90% of the powder consists either of particles within the desired size range or of agglomerates of said particles.

5 The proliposome powders of the present invention need not contain other ingredients. However pharmaceutical compositions containing the powders of the present invention may also include other pharmaceutically acceptable additives such as a pharmaceutically acceptable adjuvants, diluents and carriers. These may be added to the proliposome composition after any micronisation, or before any micronisation provided that the solvent
10 has been completely removed. Any carrier is preferably a crystalline, hydrophilic substance. A preferred carrier is crystalline lactose monohydrate. Other suitable carriers include glucose, fructose, galactose, trehalose, sucrose, maltose, raffinose, maltitol, melezitose, stachyose, lactitol, palatinite, starch, xylitol, mannitol, myoinositol, and the like, and hydrates thereof, and amino acids, for example alanine, and betaine.

15 The amount of additives present in the formulation may vary over a very wide range. In some circumstances little or no additive may be required, whereas for example it is often preferable to dilute a powder with additive, in order to improve the powder properties for use in an inhaler. In the latter case, for example, at least 50%, for example at least 70% or
20 at least 80% of the formulation may be made up of additives, the remainder being the proliposome powder. The percentage of additives may also be dependant on the potency of the biologically active compound and the optimal amount of powder for inhalation.

Where an additive, for example a carrier is present, the entire composition may be in the
25 form of particles of a size within the respirable particle size range. Alternatively the carrier may comprise coarser particles, of for example mass median diameter greater than 20 microns, or it may comprise agglomerates of the smaller particles, the agglomerates having a mass median diameter of for example greater than 20 microns, so that in either case an ordered mixture of proliposome and carrier is formed.

A further object of the present invention is the provision of a process for the preparation of the proliposome powder of the present invention, i.e. a process which yields the proliposome powder in a single phase.

- 5 Accordingly, the present invention also provides a process for the preparation of a proliposome powder for inhalation, comprising dissolving a lipid or mixture of lipids and a lipophilic biologically active component in a solvent, said lipid or mixture of lipids having a phase transition temperature below 37°C; obtaining a crystalline solvent matrix and a single lipid phase in its glassy state by freezing the solution, said freezing being carried out
10 at a temperature below the phase transition temperature of the lipid phase; and evaporating the frozen solvent at a temperature below the phase transition temperature of the lipid phase.

- Freezing of the solution and solvent evaporation may be effected by conventional methods,
15 for example in a conventional freeze-drier. For example the solution of lipids and biologically active component may be poured onto the shelves of a freeze-drier and the temperature lowered to freeze the solution. Solvent evaporation may then be achieved for example by lowering the pressure in the freeze-drying chamber; the resulting powder may be scraped from the shelves of the chamber and optionally passed through a sieve.

20

The freeze-dried powder may if necessary be subjected to further processing in order to obtain particles within the respirable particle size range; for example the freeze-dried powder may be micronised to give respirable particles, for example using an air jet mill.

- 25 The freezing of the solution of biologically active component and lipids is carried out in a manner which produces a single lipid phase in the frozen solvent matrix. The production of a single lipid phase is controlled by the final temperature and the rate of freezing of the solution; the optimum rate of freezing of any particular solution will be somewhere between the time necessary for crystallisation of the solvent in question and the time
30 necessary for crystallisation of the lipids and active component and may be determined by a

person skilled in the art, simply by trial and error. The optimal final temperature should be 10-20°C below the glass transition temperature of the lipid phase. For example a powder X-ray method may be used to monitor crystallinity and a differential scanning calorimeter may be used for monitoring the degree of incorporation of biologically active component
5 into the liposomes after hydration.

The solvent must have the capacity to dissolve the lipids and the biologically active component completely since it is essential that all the components are in solution prior to freezing in order to avoid precipitation or phase-separation which will give rise to a powder
10 with more than one phase. In addition the solvent should be toxicologically acceptable, have an appropriate freezing point and preferably a high vapour pressure. The solvent may be for example an organic solvent, for example an alcohol, or a mixture of aqueous and organic solvents. The preferred solvent for use in the present invention is tertiary butanol.

15 The powder may optionally be agglomerated into small spheres, in order to control the cohesiveness of the powder. The spheres should preferably be not larger than 1 mm in diameter; spheres larger than this may be removed for example by sieving. Any agglomerates should be friable, so that they may easily be deagglomerated for example in a powder inhaler.

20

The proliposome powder of the present invention is useful for the local or systemic treatment of diseases and may be administered for example via the upper and lower respiratory tract, including by the nasal route. As such the present invention also provides said proliposome powder for use in therapy; the use of the proliposome powder in the
25 manufacture of a medicament for the treatment of diseases via the respiratory tract; and a method for the treatment of a patient in need of therapy, comprising administering to said patient a therapeutically effective amount of the proliposome powder of the present invention.

For example the proliposome powder of the present invention may be used in the treatment of inflammatory diseases in the respiratory tract, for example asthma, rhinitis, alveolitis, bronchiolitis and bronchitis.

- 5 Administration to the respiratory tract may be effected for example using a dry powder inhaler or a pressurised aerosol inhaler.

Suitable dry powder inhalers include dose inhalers, for example the single dose inhaler known by the trade mark Monohaler® and multi-dose inhalers, for example a multi-dose,
10 breath-actuated dry powder inhaler such as the inhaler known by the trade mark Turbuhaler®.

While the proliposome powder of the present invention is particularly adapted for administration by inhalation, it may also be included in formulations adapted for other
15 forms of delivery. For example oral, topical and injectable formulations may be prepared, for use in the treatment of for example inflammatory joint diseases, for example arthritis, skin diseases, and intestinal bowel diseases.

The following Examples are intended to illustrate, but not limit, the scope of the invention.

20

Example 1

Rofleponide palmitate (10 parts), DPPC (63 parts), DMPC (24 parts) and NaDPPG (3 parts) were dissolved in tertiary butanol (1300 parts) at 80°C. The solution was poured onto the shelves of a freeze-dryer cooled to -35°C. The solution had reached this
25 temperature after about 30 minutes; the pressure in the freeze-dryer was then reduced in order to induce sublimation of the solvent. While the rate of sublimation could be adjusted by decreasing the pressure and increasing the temperature, the temperature throughout the process was not allowed to exceed -10°C. Freeze-drying was continued until all the solvent had been removed. The resulting powder was scraped from the shelves of the freeze-dryer
30 and passed through a sieve.

This powder was micronised in an air jet mill to a powder particle size of less than 5 μm . The micronised powder was mixed with lactose monohydrate (20 parts powder: 80 parts lactose monohydrate) by a sieving process and the mixture further homogenised by micronising at low pressure, in a jet mill.

5

The powder mixture was agglomerated into spheres no larger than 1 mm, using standard techniques. Larger spheres were removed by sieving. The agglomerated powder was filled into a Turbuhaler® dry powder inhaler.

10 Example 2

The procedure of Example 1 was repeated with freezing times of 6 hours, 17 hours and 24 hours.

Comparative Example

- 15 The lipids and active component of Example 1 are simply dry mixed together. The resultant powder is a multi-phase system comprising separate particles of the active component and of the lipids.

Example 3

- 20 The procedure of Example 1 is repeated using the following lipid mixtures having a phase transition temperature below 37°C:

DPSM/DPSM

e-Lecithin/Cholesterol

s-Lecithin/Cholesterol

25

Example 4

The procedure of Example 1 is repeated with the following active components:

rofleponide-21-myristate

rofleponide-21-laurate

rofleponide-21-caprate

rofleponide-21-caprylate

rofleponide-21-stearate

5 Powder analysis

X-ray powder diffraction carried out on the powder mixture of Examples 1 and 2 showed that no crystalline state was present in the powder. The powder of the Comparative Example contained the active component in the crystalline state.

10 Incorporation of active component into the liposomes

The proliposome powders of Examples 1 and 2 were hydrated and the degree of incorporation of the active component was measured using differential scanning calorimetry methods. The DSC showed that the active component was fully incorporated into the liposomes. DSC carried out on the powder of the Comparative Example showed
15 substantially no incorporation of the active component into the liposome.

Ester hydrolysis

The degree of hydrolysis of the proliposome powder of Example 1 and the Comparative Example to the active principal was investigated. The proliposome powders of Examples 1
20 and 2 and the Comparative Example (50µM of the steroid ester in each case) were hydrated with water and heated to 50°C for 15 minutes. Thereafter the samples were incubated at 37°C in the presence of porcine pancreas lipase (2mg/ml) in a buffer (1mM EDTA, 80mM KCl, 10 mM HEPES, pH 7.4) and periodically sonicated for varying lengths of time of up to 120 minutes. The samples were analysed by HPLC methods to determine how much of
25 the ester had been hydrolysed to the active principal.

94% of the proliposome powder of Example 1 was hydrolysed to the active principal, compared with just 2% of the powder of the Comparative Example.

Pharmacological studies

Anti-oedema efficacy was determined using the Sephadex model on rats as described by L. Källström et al, in Agents and Actions 17(3/4) 355 (1985).

- 5 Samples of the powders of Example 1 and the Comparative Example were suspended in cold saline and given by intratracheal injection to the left lung of male Sprague-Dawley rats. After one hour an inflammation process was provoked by intratracheal instillation of Sephadex beads (5mg/kg) to both left and right lungs. The resulting interstitial oedema was quantified after 20 hours by determining the weight of the right and left lungs. The
10 decrease in lung weight was taken to be indicative of the pharmacological effect of the powders. The lung weight of the rats treated with the proliposome powder of Example 1 had decreased 40 times more than the lung weight of the rats treated with the powder of the Comparative Example: that is, the efficacy of the proliposome powder according to the invention was 40 times greater than the efficacy of the powder of the Comparative
15 Example.

Inhalation studies

- Beagle dogs were anaesthetised, intubated, and exposed to a powder aerosol of the formulation of Example 1 or of the Comparative Example. The aerosol was generated from
20 a powder tablet using a Wright Dust Feed apparatus operated at 1800 rpm. Aerosol concentration (Casella 950 AMS), tidal volume, inspired tidal volume and breathing frequency were recorded during inhalation. The target inhaled dose was 25µg rofleponide palmitate/kg body weight. Plasma samples were taken regularly following inhalation. Bioavailability was calculated by comparison with plasma concentrations of rofleponide
25 following intravenous administration. The bioavailability of rofleponide following administration of the powder according to Example 1 was close to 100%, whereas the bioavailability of rofleponide following administration of the powder of the Comparative Example was not measurable.

Claims

1. A proliposome powder, said powder comprising in a single phase discrete particles of a biologically active component together with a lipid or mixture of lipids having a phase transition temperature of below 37°C.
5
2. A proliposome powder as claimed in claim 1, comprising one or more lipids selected from natural and synthetic phosphoglycerolipids, sphingolipids and digalactosylglycerlipids.
10
3. A proliposome powder as claimed in claim 1 or claim 2, comprising a mixture of lipids selected from the mixtures SM/PC, SM/Cholesterol, ePC/Cholesterol, sPC/Cholesterol, PC/PS/Cholesterol, DMPC/DPPC, DMPC/DPPC/CH, DMPC/CH, DPPC/DOPC, DPPC/DOPC/CH, DLPC/DPPC, DLPC/DPPC/CH, DLPC/DMPC,
15 DLPC/DMPC/CH, DOPC/DSPC.
4. A proliposome powder as claimed in any of claims 1-3, comprising DPPC, DMPC, or a mixture of DPPC and DMPC.
- 20 5. A proliposome powder as claim 4, wherein the mixture comprises at least 10% DMPC.
6. A proliposome powder as claimed in any of claims 1-5, additionally including a charged lipid.
25
7. A proliposome powder as claimed in claim 6, wherein the charged lipid is selected from DMPG, DPPG, DMPA and SA.

8. A proliposome powder as claimed in any preceding claim, wherein the active component is selected from antiinflammatory drugs, bronchorelaxing drugs, antihistamines, cyclooxygenase inhibitors, leukotriene antagonists, PLA2 inhibitors, PAF antagonists and prophylactics of asthma.

5

9. A proliposome powder as claimed in any preceding claim, wherein the active component comprises a glucocorticosteroid.

10. A proliposome powder as claimed in any preceding claim, wherein the active component comprises a β -2 agonist.

11. A proliposome powder as claimed in any preceding claim, wherein the active component comprises a steroid which is esterified in the 21 position with a fatty acid of at least 8 carbon atoms.

15

12. A proliposome powder as claimed in any preceding claim, wherein the active component comprises a steroid which is esterified in the 21 position with a fatty acid of at least 10 carbon atoms.

20 13. A proliposome powder as claimed in any preceding claim, wherein the active component comprises a steroid which is esterified in the 21 position with a fatty acid of at least 12 carbon atoms.

25 14. A proliposome powder as claimed in any preceding claim, wherein the active component comprises a steroid-21-palmitate.

15. A proliposome powder as claimed in any preceding claim, wherein the active component comprises rofleponide palmitate.

16. A proliposome powder as claimed in any preceding claim, wherein at least 50% of the powder comprises particles having a diameter of less than 10 microns.
17. A proliposome powder as claimed in any preceding claim, wherein at least 60% of the powder comprises particles having a diameter of less than 10 microns.
18. A proliposome powder as claimed in any preceding claim, wherein at least 70% of the powder comprises particles having a diameter of less than 10 microns.
19. A proliposome powder as claimed in any preceding claim, wherein at least 80% of the powder comprises particles having a diameter of less than 10 microns.
20. A proliposome powder as claimed in any preceding claim, wherein at least 90% of the powder comprises particles having a diameter of less than 10 microns.
21. A proliposome powder as claimed in any of claims 16- 20 wherein the particles have a diameter of 0.01-10 microns.
22. A proliposome powder as claimed in any of claims 16-20 wherein the particles have a diameter of 0.1-6 microns.
23. A proliposome powder as claimed in any of claims 16-20 wherein the particles have a diameter of 0.1-5 microns.
24. A proliposome powder as claimed in any preceding claim, comprising agglomerated particles.
25. A pharmaceutical composition comprising a proliposome powder as claimed in any of claims 1-24.

26. A pharmaceutical composition as claimed in claim 25, comprising a pharmaceutically acceptable carrier.

27. A pharmaceutical composition as claimed in claim 26, wherein the carrier is
5 crystalline and hydrophilic.

28. A pharmaceutical composition as claimed in claim 26, wherein the carrier is crystalline lactose monohydrate.

10 29. A pharmaceutical composition as claimed in claim 26, wherein the carrier is selected from glucose, fructose, galactose, trehalose, sucrose, maltose, raffinose, maltitol, melezitose, stachyose, lactitol, palatinase, starch, xylitol, mannitol, myoinositol, and hydrates thereof, and amino acids.

15 30. A pharmaceutical composition as claimed in any of claims 16-29, wherein the carrier comprises particles of mass median diameter greater than 20 microns.

31. A pharmaceutical composition as claimed in any of claims 16-29, wherein the carrier comprises particles of mass median diameter less than 10 microns or agglomerates
20 of said particles.

32. A process for the manufacture of a proliposome powder as claimed in any of claims 1-15, comprising dissolving a lipid or mixture of lipids and a lipophilic biologically active component in a solvent, said lipid or mixture of lipids having a phase transition
25 temperature of below 37°C; obtaining a crystalline solvent matrix and a single lipid phase in its glassy state by freezing the solution, said freezing being carried out at a temperature below the phase transition temperature of the lipid phase; and evaporating the frozen solvent at a temperature below the phase transition temperature of the lipid phase.

33. A process as claimed in claim 32, additionally comprising the step of micronising the freeze-dried powder to obtain particles within the respirable particle size range.
34. A process as claimed in claim 32 or 33, wherein freezing and solvent evaporation
5 are effected in a freeze-drier.
35. A process as claimed in any of claims 32-34, wherein the solvent comprises an organic solvent.
- 10 36. A process as claimed in claim 35, wherein the solvent comprises an alcohol.
37. A process as claimed in claim 36, wherein the solvent comprises tertiary butanol.
38. A process as claimed in any of claims 32-37, additionally comprising the step of
15 agglomerating the particles in to spheres of diameter 1mm or less.
39. A proliposome powder as claimed in any of claims 1-15 for use in therapy.
40. Use of a proliposome powder as claimed in any of claims 1-15 in the manufacture
20 of a medicament for the treatment of diseases via the respiratory tract.
41. A method of treating a patient in need of therapy, comprising administering to said patient a therapeutically effective amount of a proliposome powder as claimed in any of claims 1-15.
25
42. A dry powder inhaler device containing a proliposome powder as claimed in any of claims 1-15.
43. A dry powder inhaler device as claimed in claim 42, wherein the inhaler is a single
30 dose inhaler.

44. A dry powder inhaler device as claimed in claim 42, wherein the inhaler is a multi dose inhaler.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 95/01560

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61K 9/127, A61K 9/72, A61K 31/56

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EMBASE, MEDLINE, WPI, WPIL, CLAIMS, CA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Journal of Pharmaceutical Sciences, Volume 75, No 4, 1986, Nicholas I. Payne et al, "Proliposomes: A Novel Solution to an Old Problem", page 325, page 326, column 2, line 21 - line 24	1-2
A	--	3-40,42-44
A	US 5053217 A (STEVEN LEHIGH), 1 October 1991 (01.10.91)	1-40,42-44
	--	
A	EP 0357005 A1 (NIPPON FINE CHEMICAL CO., LTD.), 7 March 1990 (07.03.90)	1-40,42-44
	--	

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

Z document member of the same patent family

Date of the actual completion of the international search

27 March 1996

Date of mailing of the international search report

02 -04- 1996

Name and mailing address of the ISA/
 Swedish Patent Office
 Box 5055, S-102 42 STOCKHOLM
 Facsimile No. +46 8 666 02 86

Authorized officer

Anneli Jönsson

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 95/01560

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0260241 A1 (AKTIEBOLAGET DRACO), 16 March 1988 (16.03.88) -- -----	1-40, 42-44

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 95/01560

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 41
because they relate to subject matter not required to be searched by this Authority, namely:
See PCT Rule 39.1(iv): Methods for treatment of the human or animal
body by surgery or therapy, as well as diagnostic methods.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such
an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

05/02/96

International application No.

PCT/SE 95/01560

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
US-A-	5053217	01/10/91	DE-A-	3585967	11/06/92
			EP-A, A, A	0158441	16/10/85
			SE-T3-	0158441	
			JP-B-	7053661	07/06/95
			JP-A-	61044808	04/03/86
			US-A-	5004611	02/04/91
			US-A-	5141674	25/08/92
EP-A1-	0357005	07/03/90	DE-U-	6890511	08/04/93
			JP-A-	2167218	27/06/90
			US-A-	5096629	17/03/92
EP-A1-	0260241	16/03/88	AU-B, B-	603139	08/11/90
			AU-A-	7913387	07/04/88
			CA-A-	1256798	04/07/89
			EP-A-	0282537	21/09/88
			JP-T-	1500668	09/03/89
			WO-A-	8801862	24/03/88
			ZA-A-	8706641	14/03/88